FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to experimental pharmacology, novel biologically active compounds of general formula I, representing 2-morpholino-5-phenyl-6H-1,3,4-thiadiazin, hydrobromide (L-17); 2-morpholino-5-(4′-fluorophenyl)-6H-1,3,4-thiadiazin, hydrobromide (L-31), or general formula II: 2-amino propyl morpholino-5-phenyl-6H-1,3,4-thiadiazin, dihydrobromide (L-14); 2-amino propyl morpholino-5-(4′-fluorophenyl)-6H-1,3,4-thiadiazin, dihydrobromide (L-91) as agent for correction of experimental alloxan diabetes mellitus.
EFFECT: technical outcome is above compounds at intramuscular introduction in dosage of 40 mg/kg have antidiabetics action in development of alloxan diabetes in rats.